Avenir® Cemented Hip Stem - PMCF

Prospective Post Market Clinical Follow-up Study of the Avenir® Cemented Hip Stem

The objective of this post-market clinical follow-up study is to confirm the safety and performance of the Avenir® Cemented Hip stem when used in primary total hip arthroplasty.

Study Overview

• Status: Active, not recruiting
• Conditions: Femoral Neck Fractures; Congenital Hip Dysplasia; Primary Osteoarthritis; Femoral Head Necrosis; Sequelae From Previous Hip Surgery; Osteotomies; Post-Traumatic Osteoarthritis of Hip

Detailed Description

This is a multicenter, prospective, non-controlled post-market clinical follow-up study to fulfill the post market surveillance obligations according to Medical Device Directive and MEDDEV 2.12-2.

The objectives of this study are to confirm the safety and performance of the Avenir Cemented Hip Stem when used in primary total hip arthroplasty at 6 weeks to 6 months, 1, 2, 3, 5, 7 and 10 years post-operatively.

The Avenir Cemented Hip Stem is a straight double-tapered stem offering 9 standard and 9 lateralized versions, the same as the uncemented version, the Avenir-Mueller Stem.

Safety will be evaluated by monitoring the frequency and incidence of adverse events and through radiographic review.

Performance will be based on the implant survival, overall pain and functional performances, subject quality-of-life and radiographic parameters of study subjects who received the Avenir® Cemented Hip stem.

Implant survival will be based on removal or intended removal of the device.

A total of 130 patients will be enrolled into the study at up to 4 sites.

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• Belgium
  • Brussels Capital
    • Woluwe-Saint-Lambert, Brussels Capital, Belgium, 1200
      • Cliniques Universitaires St-Luc UCL
• France
  • Auvergne-Rhône-Alpes
    • Clermont-Ferrand, Auvergne-Rhône-Alpes, France, 63003
      • Hôpital Gabriel Montpied - Service de chirurgie Orthopédique
  • Occitanie
    • Montpellier, Occitanie, France, 34295
      • Hopital Lapeyronie - Service Orthopédie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients who:

• are in need of a primary total hip arthroplasty
• receive the Avenir® Cemented Hip Stem and compatible femoral head and acetabular cup
• meet all the inclusion criteria and none of the exclusion criteria

Description

Inclusion Criteria:

• Patient is 18 years of age minimum.
• Patient is suffering from severe hip pain and disability requiring primary unilateral or bilateral total hip arthroplasty based on physical exam and medical history.
• Patient is willing and able to cooperate in the required post-operative therapy.
• Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.

Exclusion Criteria:

• Patient is unwilling or unable to give consent, or to comply with the follow-up program.
• Acute, chronic, local, or systemic infections.
• Severe muscular, neural, or vascular diseases that endanger the limbs involved.
• Lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible.
• Total or partial absence of the muscular or ligamentous apparatus.
• Any concomitant diseases that can jeopardize the functioning and the success of the implant.
• Allergy to the implanted material, especially to metal (e.g., stainless steel).
• Local bone tumors and/or cysts.
• Pregnancy
• Skeletal immaturity
• Patients who have any condition that would in the judgment of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, a known drug abuser or alcoholic or anyone who cannot understand what is required of them.
• Patients with plans to relocate during the study follow-up period.
• For patients biologically younger than 60 years with joint disease, a different reconstruction operation (e.g., osteotomy) or arthrodesis may be indicated.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Patients who received the Avenir® Cemented Hip Stem; Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Implant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method	10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The results of the hip surgery will be determined by the Harris Hip Score	The Harris Hip Score is a questionnaire filled by the surgeon with the patient who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities (stair use, using public transportation, sitting, and managing shoes and socks) and gait (limp, support needed, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).	10 years
The patient's quality-of-life will be determined by the EQ-5D score	EQ-5D is a standardized instrument for measuring health status. It is made up for two components. The description part: health status is measured in five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself. Usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have. In anxiety/depression dimension, it asks how anxious or depressed they are. Visual analogue scale: The patient marks his health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100. The bottom rate (0) corresponds to " the worst health you can imagine", and the highest rate (100) corresponds to "the best health you can imagine".	10 years
Abnormalities determined on X-rays in the bone region surrounding the implant will be reported		10 years
Number of patient with adverse events related to the implant will be reported	Adverse events include: dislocations of the hip, revisions and removals of the implants	10 years

Collaborators and Investigators

• Sponsor: Zimmer Biomet
• Investigators: Study Director: Hassan Achakri, Zimmer Biomet

Study record dates

Study Major Dates

• Study Start (Actual): November 18, 2015
• Primary Completion (Estimated): November 1, 2030
• Study Completion (Estimated): November 1, 2030

Study Registration Dates

• First Submitted: December 11, 2017
• First Submitted That Met QC Criteria: January 4, 2018
• First Posted (Actual): January 10, 2018

Study Record Updates

• Last Update Posted (Estimated): November 25, 2025
• Last Update Submitted That Met QC Criteria: November 19, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: Total hip arthroplasty; Hip implant
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Wounds and Injuries; Leg Injuries; Fractures, Bone; Musculoskeletal Abnormalities; Congenital Abnormalities; Femoral Fractures; Hip Injuries; Hip Fractures; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Developmental Dysplasia of the Hip; Femoral Neck Fractures; Hip Dislocation, Congenital
• Other Study ID Numbers: CME2013-03H

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No